New guidance released on genetic testing for dyslipidemia patients

2020 04 23 16 00 2942 Genetic Engineering Dna Rna 400

The National Lipid Association (NLA) has released a scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia.

The statement provides information for healthcare providers on genetic testing, including risks and benefits, as patients may require testing to help confirm a diagnosis or guide therapy.

The statement discusses the importance of genetic counseling before and after genetic testing and outlines potential limitations of testing in dyslipidemia. It also has a detailed table of recommendations to guide healthcare professionals.

The article, "Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association," is in press with the Journal of Clinical Lipidology and can be accessed through the journal or on the NLA website.

Page 1 of 190
Next Page